GlassScriptPhysician profile
James T Elliott
NPI 1114919487
$3,493.36
in general payments reported to CMS, 2019-2025
30 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $292 · 2021: $455 · 2022: $385 · 2023: $266 · 2024: $873 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,126.26 | 2023-2025 | Biomonitor, Amvia Edge, Rivacor 7 Dr-T |
| Boston Scientific Corporation | $375.17 | 2019-2024 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $354.81 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $344.92 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $220.35 | 2021-2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $165.97 | 2021-2025 | |
| Amgen INC. | $134.64 | 2019-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $102.59 | 2019-2020 | |
| Novo Nordisk INC | $81.23 | 2024-2025 | Wegovy |
| Medtronic Vascular, INC. | $71.47 | 2019-2020 | |
| Abbott Laboratories | $66.88 | 2020-2022 | |
| Pfizer INC. | $56.44 | 2022-2025 | |
| Cardiovascular Systems INC. | $52.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.99 | 2022-2024 | Verquvo |
| Cvrx, INC. | $45.41 | 2025 | Barostim Neo System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $32.06 | 2023 | Injectafer |
| Edwards Lifesciences Corporation | $31.41 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $21.93 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.91 | 2025 | Jardiance |
| Abiomed | $21.57 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.70 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $18.84 | 2023 | Arcalyst |
| Grifols USA, LLC | $16.72 | 2019 | |
| Amarin Pharma, INC. | $15.00 | 2021 | |
| Chiesi USA, INC. | $13.57 | 2021 | |
| Shockwave Medical, INC | $12.76 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Esperion Therapeutics, INC. | $12.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.22 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.